Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectations

摘要

ObjectiveThe availability of weekly subcutaneous infusions of subcutaneous immunoglobulin (SCIg) provides an additional therapeutic option for patients with primary immunodeficiency disease. With proper patient education, individuals can safely transition to SCIg therapy and experience minimal side effects.